This bill amends the Federal Food, Drug, and Cosmetic Act to enhance transparency for generic drug developers. It requires the Secretary of Health and Human Services, upon request, to inform a generic drug applicant whether their proposed drug is qualitatively and quantitatively identical to the reference listed drug, especially for drugs needing the same inactive ingredients or using in vitro bioequivalence. This provision aims to streamline the development process for generic medications by providing crucial information early. Should the Secretary determine that the generic drug is not qualitatively or quantitatively the same, the bill mandates the disclosure of the specific ingredients causing the discrepancy and the extent of any quantitative deviation . Once a determination of sameness is made, it generally cannot be rescinded after application submission, except under specific circumstances like a change in the listed drug's formulation due to safety concerns or a written determination of error. The legislation also directs the Secretary to issue guidance within one year on how these qualitative and quantitative determinations will be made, including considerations for pH adjusters , ensuring consistent application of these new transparency measures.